Health ProductsPublic Communication

INVIRASE (saquinavir mesylate) - Need for Electrocardiogram Monitoring in Patients - For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Hoffman-La Roche Limited.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Public Communication - Health Canada Endorsed Important Safety Information on INVIRASE

November 2, 2010

Subject: Updated Safety Information for INVIRASE® (saquinavir mesylate): Specific Guidance on Monitoring Heart Activity Using Electrocardiography

Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform patients of safety updates to the prescribing information for INVIRASE (saquinavir mesylate).

INVIRASE is authorized for the treatment of HIV-1 infected adult patients. INVIRASE should only be given in combination with ritonavir and other antiretroviral products.

The Canadian Product Monograph, including Consumer Information, for INVIRASE has been revised to further emphasize the following safety concerns:

To inform health care professionals regarding the need to:

  • Perform electrocardiogram (ECG) monitoring of patients who are starting treatment with ritonavir and INVIRASE;
  • Perform ECG monitoring of patients who are taking other medications that may affect heart rhythm, while taking ritonavir and INVIRASE.

The current Canadian prescribing information for INVIRASE (Product Monograph) can be accessed on the Roche Canada Web site or by performing a search in Health Canada's Drug Product Database.

Please speak with your doctor or pharmacist if you have any related concerns or if you experience any other unexpected effects while taking INVIRASE.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving INVIRASE should be reported to Hoffmann-La Roche Limited or Health Canada at the following addresses:

Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa, Ontario   K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

Should you have any questions or require additional information regarding the use of INVIRASE, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time.

Sincerely,

original signed by

Lorenzo Biondi,
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime